Avenzo Therapeutics Announces Exclusive Global License Agreement With DualityBio

New York – January 7, 2025 – Cooley advised Avenzo Therapeutics, a clinical-stage biotechnology company developing next-generation oncology therapies, on its exclusive license agreement with Duality Biotherapeutics (DualityBio), pursuant to which Avenzo will develop, manufacture and commercialize AVZO-1418/DB-1418 – a potential best-in-class epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 3 (HER3) bispecific antibody-drug conjugate (ADC) – globally (excluding Greater China). Under the terms of the agreement, DualityBio will receive an up-front payment of $50 million and will be eligible for up to approximately $1.15 billion in development, regulatory and commercial milestone payments. Additionally, DualityBio is eligible to receive tiered royalties on sales in Avenzo’s territory.

Life sciences corporate partnering and licensing partner Charity Williams, along with associates Chen Chen and Jonathan Kaufman, led the Cooley team advising Avenzo, with support from tax associate Amanda Pacheco and regulatory of counsel Natasha Leskovsek and associate Elizabeth Caruso. Intellectual property diligence was led by Kimberly Bolin and Mika Mayer with support from Mark Westwood, Nitasha Bennet, and Connie Tong.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.